Development and evaluation of enteric-coated penicillamine tablets.
Commercially available 250-mg penicillamine tablets were converted into enteric-coated tablets. Based on in vitro dissolution and disintegration tests, tablets coated with five layers of a cellulose acetate phthalate formulation by a modified pan coating technique were judged to be superior to other coated tablets. These tablets resisted disintegration in simulated gastric fluid over a 4-h period and disintegrated in an average of 21 min in simulated intestinal fluid. Enteric-coated penicillamine tablets were tested in vivo in nine weanling pigs divided into three groups: a negative control group, a test group dosed with enteric-coated penicillamine tablets, and a positive control group dosed with uncoated tablets. The incidence of GI tract bleeding, as determined by daily occult blood tests of the stools, was significantly less in the animals receiving the enteric-coated tablets when compared with the positive control group. The enteric-coated dosage form appeared to decrease GI tract irritation caused by penicillamine. Plasma concentration-time curves for penicillamine in the pigs were similar in shape to those reported in humans. Atypical double peaks occur in both species. Relative bioavailability of the enteric-coated tablet was found to be 67% when compared with the uncoated tablet. This apparent reduction is probably due to a large intrasubject variation in areas under the plasma concentration-time curves and not to a dosage form effect.
D000818:Animals; D001682:Biological Availability; D001835:Body Weight; D004355:Drug Stability; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D010396:Penicillamine / Q000008:administration & dosage* / Q000378:metabolism / Q000633:toxicity; D012995:Solubility; D013552:Swine; D013608:Tablets, Enteric-Coated; D013997:Time Factors
D013608:Tablets, Enteric-Coated; D010396:Penicillamine